Key Performance

Earnings Score: N/A
Momentum Score: 77
True Yield: N/A
Financial Health Score: N/A

Latest Research & News

Scilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026

Scilex Holding Company's board approved a dividend distribution of Semnur Pharmaceuticals common stock to its shareholders, with a record date of June 1, 2026. Scilex will distribute approximately 10.7 million shares of its ~186 million Semnur holdings to eligible equity holders at a 1:1 ratio. The payment date will be determined by subsequent board resolutions within 60 days of the record date, though the board retains the right to change the record date or revoke the dividend.

05/22/2026, 1:15 PM • Benzinga

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

Scilex Holding Company announced that its subsidiaries ACEA Therapeutics and ACEA Pharma entered into a definitive agreement to sell 100% of ACEA Pharma's equity to Phoenix Asia Holdings Limited for $1 billion in newly-issued shares. Upon closing, Phoenix will be renamed ACEA Pharma and listed on Nasdaq, with ACEA Thera retaining approximately 82% ownership. The transaction is expected to close by end of Q2 2026, subject to regulatory and stock exchange approvals.

05/05/2026, 1:00 PM • GlobeNewswire

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

Scilex Holding Company's subsidiaries ACEA Therapeutics and ACEA Pharma have entered into a definitive stock acquisition agreement with Phoenix Asia Holdings Limited. Under the deal, ACEA will transfer 100% of ACEA Pharma's equity to Phoenix in exchange for 100 million newly-issued ordinary shares at $10 per share, valuing the transaction at $1 billion. Upon closing, Phoenix will be renamed ACEA Pharma, Inc. and its stock is expected to list on Nasdaq. The transaction is expected to close by end of Q2 2026, subject to regulatory approvals.

05/05/2026, 1:00 PM • Benzinga

Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026

Scilex Holding Company's board approved May 26, 2026 as the payment date for distributing approximately 81.4 million Dream Bowl Meme Coin I tokens to shareholders, with a record date of April 30, 2026. Shareholders will receive 5 tokens per share of common stock. The company plans to list the tokens on the Biconomy cryptocurrency exchange in Q2 2026. The dividend is explicitly stated to have no investment value and is conditioned on the board not revoking it prior to payment.

05/04/2026, 6:00 AM • GlobeNewswire

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

Scilex Holding Company (Nasdaq: SCLX) announced a $20 million strategic investment in Quantum Scan Holdings, Inc., a medical technology company focused on preventive diagnosis and prognosis. The investment aims to support Quantum Scan's development of advanced diagnostic platforms and healthcare solutions. Scilex views this investment as synergistic with its existing investment in Datavault AI and aligned with its strategic priorities in advancing healthcare solutions.

01/30/2026, 9:00 AM • GlobeNewswire

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, closing out option agreement obligations and bringing total returns to $118 million on its original $99.5 million investment. The company's board approved a $0.25 per share cash dividend (~$10.5 million aggregate) to be paid on January 26, 2026. Oramed retains $39 million in outstanding debt, convertible notes, warrants, and royalty interests with Scilex.

01/07/2026, 8:55 AM • Benzinga

Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

Scilex Holding Company announced the appointment of Kasowitz LLP and founding partner Marc Kasowitz as its litigation and intellectual property counsel. The firm will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, and strategic IP governance as the company advances its pharmaceutical assets and development pipeline.

01/02/2026, 9:00 AM • GlobeNewswire

Datavault AI Inc. (나스닥: DVLT), Datavault AI 적격 등재 주주 및 Scilex 보통주 보유자에게 Dream Bowl 밈 코인 토큰을 2025년 12월 24일 배포한다고 발표

Datavault AI will distribute Dream Bowl Meme Coin tokens to its eligible shareholders and Scilex common stock holders on December 24, 2025, as a commemorative digital collectible for the upcoming Dream Bowl XIV event.